PACE4 regulates apoptosis in human pancreatic cancer Panc‑1 cells via the mitochondrial signaling pathway

Tian,Xiao‑Feng; Huang,Guo‑Min; Zang,Hong‑Liang; Cao,Hong

doi:10.3892/mmr.2016.5885

PACE4 regulates apoptosis in human pancreatic cancer Panc‑1 cells via the mitochondrial signaling pathway

Authors:
- Xiao‑Feng Tian
- Guo‑Min Huang
- Hong‑Liang Zang
- Hong Cao
View Affiliations

Affiliations: Department of General Surgery, Xinmin Branch of The China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: October 25, 2016 https://doi.org/10.3892/mmr.2016.5885
Pages: 5205-5210

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have demonstrated the overexpression of paired basic amino acid cleaving enzyme 4 (PACE4) mRNA in prostate cancer tissues. This overexpression is correlated with higher circulating protein levels in certain patients, however, the role of PACE4 in apoptosis and the potential molecular mechanisms of pancreatic cancer remain to be elucidated. The aim of the present study was to investigate the effect and potential molecular mechanisms of PACE4 on apoptosis in the Panc‑1 pancreatic cancer cell line. Cell proliferation was assessed using a Cell Counting Kit‑8 assay. Apoptotic nuclear shrinkage was monitored using Hoechst 33258 staining. Caspase‑3/7 activities were measured using a colorimetric caspase‑glo 3/7 assay. Alterations in protein expression were monitored using Western blot analysis. The results indicated that PACE4 small interfering (si)RNA inhibited cell proliferation and activated caspase‑3/7 activities. In addition, PACE4 siRNA significantly increased apoptosis via the activation of caspase‑3 and the downregulation of anti‑apoptotic proteins, X‑linked inhibitor of apoptosis protein and phosphorylated‑Akt. In addition, the results showed deregulation of the B cell lymphoma‑2 (Bcl‑2)-associated X protein/Bcl‑2 ratio which led to the release of cytochrome c following PACE4 siRNA transfection. In conclusion, PACE4 siRNA may exert antitumor activity through the mitochondrial pathway and is expected to be a promising therapeutic strategy for the treatment of pancreatic cancer.

View Figures

View References

1	Feng J, Ma T, Ge Z, Lin J, Ding W, Chen H, Zhu W, Zhou S and Tan Y: PKM2 gene regulates the behavior of pancreatic cancer cells via mitogen-activated protein kinase pathways. Mol Med Rep. 11:2111–2117. 2015.PubMed/NCBI
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
3	Kim J, Kim YC, Fang C, Russell RC, Kim JH, Fan W, Liu R, Zhong Q and Guan KL: Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy. Cell. 152:290–303. 2013. View Article : Google Scholar : PubMed/NCBI
4	Gong L, Yang B, Xu M, Cheng B, Tang X, Zheng P, Jing Y and Wu GJ: Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production. Cancer Chemother Pharmacol. 73:69–77. 2014. View Article : Google Scholar : PubMed/NCBI
5	Min H, Xu M, Chen ZR, Zhou JD, Huang M, Zheng K and Zou XP: Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells. Cancer Chemother Pharmacol. 74:167–176. 2014. View Article : Google Scholar : PubMed/NCBI
6	Jin C, Yao L, Long J, Fu DL, Yu XJ, Yang F, Ni QX and Xu J: Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. Chin Med J (Engl). 122:284–290. 2009.PubMed/NCBI
7	Preis M and Korc M: Signaling pathways in pancreatic cancer. Crit Rev Eukaryot Gene Expr. 21:115–129. 2011. View Article : Google Scholar : PubMed/NCBI
8	Seidah NG and Prat A: The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 11:367–383. 2012. View Article : Google Scholar : PubMed/NCBI
9	Tsuji A, Sakurai K, Kiyokage E, Yamazaki T, Koide S, Toida K, Ishimura K and Matsuda Y: Secretory proprotein convertases PACE4 and PC6A are heparin-binding proteins which are localized in the extracellular matrix. Potential role of PACE4 in the activation of proproteins in the extracellular matrix. Biochim Biophys Acta. 1645:95–104. 2003. View Article : Google Scholar : PubMed/NCBI
10	Yuasa K, Masuda T, Yoshikawa C, Nagahama M, Matsuda Y and Tsuji A: Subtilisin-like proprotein convertase PACE4 is required for skeletal muscle differentiation. J Biochem. 146:407–415. 2009. View Article : Google Scholar : PubMed/NCBI
11	Sato H, Kinoshita T, Takino T, Nakayama K and Seiki M: Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett. 393:101–104. 1996. View Article : Google Scholar : PubMed/NCBI
12	Yana I and Weiss SJ: Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell. 11:2387–2401. 2000. View Article : Google Scholar : PubMed/NCBI
13	Dubois CM, Blanchette F, Laprise MH, Leduc R, Grondin F and Seidah NG: Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am J Pathol. 158:305–316. 2001. View Article : Google Scholar : PubMed/NCBI
14	Khatib AM, Siegfried G, Prat A, Luis J, Chrétien M, Metrakos P and Seidah NG: Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: Importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J Biol Chem. 276:30686–30693. 2001. View Article : Google Scholar : PubMed/NCBI
15	Hubbard FC, Goodrow TL, Liu SC, Brilliant MH, Basset P, Mains RE and Klein-Szanto AJ: Expression of PACE4 in chemically induced carcinomas is associated with spindle cell tumor conversion and increased invasive ability. Cancer Res. 57:5226–5231. 1997.PubMed/NCBI
16	Mahloogi H, Bassi DE and Klein-Szanto AJ: Malignant conversion of non-tumorigenic murine skin keratinocytes overexpressing PACE4. Carcinogenesis. 23:565–572. 2002. View Article : Google Scholar : PubMed/NCBI
17	D'Anjou F, Routhier S, Perreault JP, Latil A, Bonnel D, Foumier I, Salzet M and Day R: Molecular validation of PACE4 as a target in prostate cancer. Transl Oncol. 4:157–172. 2011. View Article : Google Scholar : PubMed/NCBI
18	Klee EW, Bondar OP, Goodmanson MK, Dyer RB, Erdogan S, Bergstralh EJ, Bergen HR III, Sebo TJ and Klee GG: Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood. Clin Chem. 58:599–609. 2012. View Article : Google Scholar : PubMed/NCBI
19	Estilo CL, O-charoenrat P, Talbot S, Socci ND, Carlson DL, Ghossein R, Williams T, Yonekawa Y, Ramanathan Y, Boyle JO, et al: Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC Cancer. 9:112009. View Article : Google Scholar : PubMed/NCBI
20	Kurokawa Y, Matoba R, Nakamori S, Takemasa I, Nagano H, Dono K, Umeshita K, Sakon M, Monden M and Kato K: PCR-array gene expression profiling of hepatocellular carcinoma. J Exp Clin Cancer Res. 23:135–141. 2004.PubMed/NCBI
21	Delic S, Lottmann N, Jetschke K, Reifenberger G and Riemenschneider MJ: Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes. Neuropathol Appl Neurobiol. 38:201–212. 2012. View Article : Google Scholar : PubMed/NCBI
22	Bassi DE, De Cicco R Lopez, Cenna J, Litwin S, Cukierman E and Klein-Szanto AJ: PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression. Cancer Res. 65:7310–7319. 2005. View Article : Google Scholar : PubMed/NCBI
23	Tait SW and Green DR: Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 11:621–632. 2010. View Article : Google Scholar : PubMed/NCBI
24	LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S and Korneluk RG: IAP-targeted therapies for cancer. Oncogene. 27:6252–6275. 2008. View Article : Google Scholar : PubMed/NCBI
25	Boonyarat C, Yenjai C, Vajragupta O and Waiwut P: Heptaphylline induces apoptosis in human colon adenocarcinoma cells through bid and Akt/NF-kB (p65) pathways. Asian Pac J Cancer Prev. 15:10483–10487. 2014. View Article : Google Scholar : PubMed/NCBI
26	Serrano ML, Sánchez-Gómez M, Bravo MM, Yakar S and LeRoith D: Differential expression of IGF-I and insulin receptor isoforms in HPV positive and negative human cervical cancer cell lines. Horm Metab Res. 40:661–667. 2008. View Article : Google Scholar : PubMed/NCBI
27	Cotter TG: Apoptosis and cancer: The genesis of a research field. Nat Rev Cancer. 9:501–507. 2009. View Article : Google Scholar : PubMed/NCBI
28	Leber B, Lin J and Andrews DW: Still embedded together binding to membranes regulates Bcl-2 protein interactions. Oncogene. 29:5221–5230. 2010. View Article : Google Scholar : PubMed/NCBI
29	Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 26:1324–1337. 2007. View Article : Google Scholar : PubMed/NCBI
30	Jiang H, Zhao PJ, Su D, Feng J and Ma SL: Paris saponin I induces apoptosis via increasing the Bax/Bcl-2 ratio and caspase-3 expression in gefitinib-resistant non-small cell lung cancer in vitro and in vivo. Mol Med Rep. 9:2265–2272. 2014.PubMed/NCBI